Literature DB >> 20970488

Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009.

Nicole P Lindsey1, J Erin Staples, James F Jones, James J Sejvar, Anne Griggs, John Iskander, Elaine R Miller, Marc Fischer.   

Abstract

We reviewed adverse events following receipt of inactivated mouse brain-derived Japanese encephalitis (JE) vaccine reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 1999 to 2009. During this period, VAERS received 300 adverse event reports following JE vaccination (24 per 100,000 doses distributed); 106 (35%) were classified as hypersensitivity reactions (8.4 per 100,000 doses) and four (1%) were classified as neurologic events (0.3 per 100,000 doses). Twenty-three (8%) reports described serious adverse events (1.8 per 100,000 doses distributed). There were no reports of encephalitis, meningitis, or Guillain-Barré syndrome. As reported previously, hypersensitivity reactions were common among persons receiving inactivated mouse brain-derived JE vaccine. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970488     DOI: 10.1016/j.vaccine.2010.10.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Immunogenicity of a live-attenuated Japanese encephalitis vaccine in children and adolescents after hematopoietic stem cell transplantation.

Authors:  S Pakakasama; S Wattanatitan; C Techasaensiri; S Yoksan; S Sirireung; S Hongeng
Journal:  Bone Marrow Transplant       Date:  2014-07-21       Impact factor: 5.483

2.  An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.

Authors:  Susan L Hills; Sann Chan Soeung; Svay Sarath; Chheng Morn; Cheam Dara; Marc Fischer; Michael C Thigpen
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

3.  Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.

Authors:  Ingrid B Rabe; Elaine R Miller; Marc Fischer; Susan L Hills
Journal:  Vaccine       Date:  2014-12-09       Impact factor: 3.641

4.  A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.

Authors:  Elina O Erra; Helena Hervius Askling; Lars Rombo; Jukka Riutta; Sirkka Vene; Sutee Yoksan; Lars Lindquist; Sari H Pakkanen; Eili Huhtamo; Olli Vapalahti; Anu Kantele
Journal:  Clin Infect Dis       Date:  2012-06-13       Impact factor: 9.079

5.  The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children.

Authors:  Hyo Jin Kwon; Soo Young Lee; Ki Hwan Kim; Dong Soo Kim; Sung Ho Cha; Dae Sun Jo; Jin Han Kang
Journal:  J Korean Med Sci       Date:  2015-04-15       Impact factor: 2.153

6.  Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Susan L Hills; Emmanuel B Walter; Robert L Atmar; Marc Fischer
Journal:  MMWR Recomm Rep       Date:  2019-07-19

7.  Safety of Japanese encephalitis vaccines.

Authors:  Ya-Li Hu; Ping-Ing Lee
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 3.452

8.  Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016.

Authors:  William L Walker; Susan L Hills; Elaine R Miller; Marc Fischer; Ingrid B Rabe
Journal:  Vaccine       Date:  2018-06-08       Impact factor: 3.641

Review 9.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

Review 10.  Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents.

Authors:  Stephen J Streatfield; Natasha Kushnir; Vidadi Yusibov
Journal:  Plant Biotechnol J       Date:  2015-10       Impact factor: 9.803

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.